June 2015 Options Now Available For Array BioPharma (ARRY)

Investors in Array BioPharma Inc. ( ARRY) saw new options begin trading today, for the June 2015 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 282 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARRY options chain for the new June 2015 contracts and identified one put and one call contract of particular interest.

The put contract at the $3.00 strike price has a current bid of 15 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $3.00, but will also collect the premium, putting the cost basis of the shares at $2.85 (before broker commissions). To an investor already interested in purchasing shares of ARRY, that could represent an attractive alternative to paying $3.54/share today.

Because the $3.00 strike represents an approximate 15% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 74%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 5.00% return on the cash commitment, or 6.47% annualized — at Stock Options Channel we call this the YieldBoost.

START SLIDESHOW:
Top YieldBoost Puts of the S&P 500 »

Below is a chart showing the trailing twelve month trading history for Array BioPharma Inc., and highlighting in green where the $3.00 strike is located relative to that history:

If you liked this article you might like

STMicroelectronics, Intercept Pharmaceuticals: 'Mad Money' Lightning Round

Watch Out For the Dominoes That Fall: Cramer's 'Mad Money' Recap (Wed 9/20/17)

Mirati Skyrockets On Positive Data - Biotech Movers

Array BioPharma Seems to Be in a New Uptrend